Imunon, Inc. Q4 FY2025 earnings call

Dr. Stacey Lindborg discussed Immunon's progress with Immunon-001, which showed overall survival benefits in ovarian cancer. The Phase II Ovation 2 study had final overall survival at 14.7 months, and patients with PARP inhibitors had over two years median overall survival increase. 2025 saw showcasing of clinical data at scientific forums, R&D day, and Ovation 3 trial enrollment ahead of plan. Dr. Douglas Fowler commented on the gynecologic community's enthusiasm, early sites exceeding enrollment forecasts, and safety data. Jeff Church reviewed financials: cash and cash equivalents $8.8M as of Dec 31, 2025; R&D expenses $7.8M in 2025 (lower than 2024); G&A expenses down 8% Y/Y; net loss $14.5M in 2025.

Goal to have approximately 80 patients enrolled in Ovation 3 trial within next 12 months and enrollment completed in 2029; Interim analyses designed with simulations, first interim expected about a year after fully enrolling trial.

Q: Have you presented final data from Ovation 2 to FDA on PARP inhibitor patient population and feedback on Ovation 3 focus?

A: Not presented OS data to FDA yet, focus on phase three trial momentum.

Q: Potential cut points for interim looks in Ovation 3?

A: First interim expected about a year after fully enrolling trial.

Q: How did final data on Ovation 2 change partnership environment?

A: New inquiries occurring, but early days.

Q: Updates from MRD study in 2026?

A: Early discussions on presenting insights.

Q: HRD status of patients in trial?

A: Important part of phase three, but will be cautious with updates.

Q: Site enrollment pace?

A: Above 0.3 points per month per site average.

Q: Additional sites and trial payment structure?

A: Focus on US sites with potential for European sites; trial structured with startup fees and fees as patients treated.